Replies to post #306 on Inovio Pharmaceuticals Inc (INO)

[Ubertino]

What I find profound is that in contrast to Gardasil, INO's VGX-3100 is therapeutic, meaning it removes the cancer from those who already have it as well as prevent the disease infecting those who do not yet have the cancer.

[humblehawk]

NEWS ~!!!

INO Awarded Follow-on Funding from the PATH Malaria Vaccine Initiative for DNA Vaccine Development
Last update: 9/15/2010 3:30:02 AM
Novel Multi-Antigen Malaria DNA Vaccine Generates Potent Immune Responses in Animal Studies
BLUE BELL, Pa., Sep 15, 2010 (BUSINESS WIRE) -- Inovio Pharmaceuticals, Inc. (INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the PATH Malaria Vaccine Initiative (MVI) has agreed to provide follow-on funding to continue evaluation and development of Inovio's malaria DNA vaccine candidate in non-human primates.
In the prior MVI-funded feasibility study, Inovio's malaria vaccine candidate induced broad-based immunity to four pre-erythrocytic malaria antigens. In the upcoming non-human primate study, Inovio's SynCon(TM)DNA vaccine platform, which targets sporozoites and the liver stage of the parasite, is delivered using Inovio's proprietary electroporation delivery technology. Humoral (antibody) and cellular (T-cell) responses will be assessed in this follow-on program, conducted by the same collaboration of vaccine experts from the University of Pennsylvania School of Medicine and Inovio.
Malaria continues to present a major healthcare challenge in the developing world and has been the focus of much attention by global public health agencies. Development of an effective vaccine against Plasmodium falciparum has been a challenge. The parasite undergoes several stages of development during its life cycle and presents different potential target antigens at each stage as it passes through its human and mosquito hosts. Inovio's vaccine candidate targets the pre-erythrocytic stage of the parasite and focuses on induction of both humoral and cellular responses against multiple target antigens. This approach is intended to help prevent infection of liver cells and to further clear those cells that, despite the antibody response, become infected. By targeting the parasite during the first days after infection, this type of vaccine may prevent the onset of malaria symptoms and further inhibit spread of the disease.
Inovio's technology has previously been shown to induce robust T-cell and antibody responses in different animal models of diseases including influenza, small-pox, HIV, and HPV. Data from the recently completed malaria immunogenicity study will be presented at the Second International Malaria Vaccines for the World Conference in Washington, DC (Sep 28-30).
Christian Loucq, MD, Director of the PATH Malaria Vaccine Initiative, stated: "MVI seeks to accelerate the development of malaria vaccines and we are pleased to continue working with Inovio's novel DNA vaccine platform and its malaria vaccine approach."
Dr. J. Joseph Kim, President and CEO of Inovio, said: "Inovio's proprietary DNA vaccine technology platform has once again induced strong immune responses for a disease with unmet treatment needs -- in this case, malaria. We recently announced best-in-class immunogenicity data from our clinical trial for our HPV/cervical cancer DNA vaccine using the same technology platform. We appreciate MVI's shared enthusiasm and commitment to advance the application of this next-generation vaccine technology against this challenging disease."
Malaria is caused by parasites that are transmitted to people through the bites of infected mosquitoes. People with malaria often experience fever, chills, and flu-like illness. Left untreated they may develop severe complications and die. Worldwide, about 2.37 billion people in 87 countries are at risk of the disease. According to WHO, in 2008 there were an estimated 247 million cases of malaria and nearly one million deaths -- mostly among children living in Africa. A vaccine to prevent malaria infection would complement currently available methods to treat or prevent malaria.
On the Internet: PATH Malaria Vaccine Initiative, PATH,

GO INO.... RNN is next ..imo...

[papaul]

You know Surf - I held a few shares after selling most and got out totally this week.

Now the news rolls in. Oh well, I grew very impatient with INO and will look elsewhere for opportunity.

Good Luck,
papaul

[JUST 10-11-12]

very nice news!

Keith

[surf1944]

6:03AM Inovio Pharma announces $24.3 mln Registered Offering (INO) 1.30 : Co announces it has agreed to sell to a single institutional investor 21,130,400 shares of its common stock and warrants to purchase up to 10,565,200 additional shares of its common stock. The shares of common stock and warrants are being offered in units consisting of one share of common stock and 0.5 of a warrant to purchase one share of common stock at a price of $1.15 per unit. The warrants have a term of five years and an exercise price of $1.40 per share. The gross proceeds of the offering are expected to be $24.3 mln and net proceeds, after deducting the placement agent's fee and estimated offering expenses payable by co, are expected to be ~$23.0 mln.